Clinical Trials Logo

Clinical Trial Summary

Extremely low birth weight infants have decreased blood levels of Vitamin A. This Vitamin A deficiency may increase the risk of infections and chronic lung disease in these infants. This study will examine the effects of Vitamin A supplementation in premature babies born weighing less than 1500 grams (3.3 lbs).


Clinical Trial Description

Vitamin A and its derivative retinoic acid (RA) have been recognized as important factors in potentiating the immune response and protecting against infection. In developing nations, Vitamin A deficiency is associated with infectious gastroenteritis and increased susceptibility to a number of infections, such as measles. RA is an important regulator of cell growth and differentiation and can augment IgM production from core blood mononuclear cells in response to a polyclonal B-cell activator. This augmentation in immunoglobulin secretion is mediated by the effects of RA on both T and B cells, in part through the production of certain cytokines (e.g., IL-6 and IL-10) important in the terminal differentiation of B-cells to plasma cells. In animal models, correction of Vitamin A deficiency improves immune response to vaccination.

Infants with extremely low birth weight have low plasma and tissue concentrations of Vitamin A. Vitamin A supplementation of pre-term infants reduces chronic lung disease and the risk of sepsis. Because the immune system of the pre-term infant is immature, the response of pre-term infants to Hepatitis B vaccine is diminished compared to full-term babies. This study will determine whether Vitamin A supplementation of pre-term infants will enhance the response of these infants to immunization with Hepatitis B vaccine. The study will also evaluate the effect of Vitamin A supplementation on survival, chronic lung disease, and infection rate.

Low birth weight pre-term infants will be randomized to receive either Vitamin A supplementation or placebo. The Vitamin A treatment group will receive 5,000 IU of Vitamin A (retinyl palmitate) by intramuscular injection 3 times weekly for 28 days starting on postnatal day 2. To avoid pain and discomfort, the placebo group will receive a sham procedure rather than a placebo saline injection. The staff of the neonatal intensive care unit will retain the responsibility for decisions regarding the use of other therapies, such as parental fluids, mechanical ventilation, glucocorticoids, hyperalimentation, and blood replacement. All infants will be assessed for potential Vitamin A toxicity. While in the neonatal intensive care unit, infants will have blood tests at Days 0, 14, 30, and 60. After discharge from the neonatal intensive care unit, patients return for clinic assessment and blood samples at Months 4, 6, and 9. Infants will be given Hepatitis B vaccine at 2, 4, and 6 months chronological age. Primary outcome measures will include Hepatitis B antibody levels, chronic lung disease, rate of infection while in the neonatal intensive care unit, and the incidence and severity of infections during the first 9 months of life. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00063596
Study type Interventional
Source Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact
Status Active, not recruiting
Phase N/A
Start date January 2000
Completion date May 2004

See also
  Status Clinical Trial Phase
Completed NCT03146351 - The Effects of Family Centered Intervention Program on Preterm Infants N/A
Completed NCT02064712 - Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates N/A
Completed NCT00365703 - Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best? N/A
Terminated NCT00179933 - The Impact of Implementing NIDCAP on Preterm Infants in the NICU N/A
Completed NCT00114543 - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Phase 3
Terminated NCT05030012 - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants N/A
Completed NCT00552383 - The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care N/A
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Completed NCT06308471 - Effect of Baby Massage on Oral Motor Skills of Premature Babies N/A
Completed NCT01863043 - Aspiration of Residual Gastric Contents N/A
Completed NCT05462509 - Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda N/A
Not yet recruiting NCT06109350 - The Effect of Physical Therapy Intervention on Motor Performance in Bhutanese Preterm Infants N/A
Completed NCT03551600 - Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Terminated NCT02599545 - Testosterone and Cortisol Levels in Infants
Completed NCT02611284 - Less Invasive Beractant Administration in Preterm Infants N/A
Completed NCT01193270 - Vitamin E for Extremely Preterm Infants Phase 1
Withdrawn NCT00536445 - Use of NAVA in Intubated Preterm Phase 1/Phase 2
Completed NCT00455169 - Influenza Vaccine in Premature Infants Phase 4
Completed NCT00579553 - Comparing IM vs. Vaginal Progesterone for Pre-term Birth N/A
Completed NCT01203423 - Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study